JP4589122B2 - ホスホジエステラーゼ10a阻害剤 - Google Patents
ホスホジエステラーゼ10a阻害剤 Download PDFInfo
- Publication number
- JP4589122B2 JP4589122B2 JP2004556869A JP2004556869A JP4589122B2 JP 4589122 B2 JP4589122 B2 JP 4589122B2 JP 2004556869 A JP2004556869 A JP 2004556869A JP 2004556869 A JP2004556869 A JP 2004556869A JP 4589122 B2 JP4589122 B2 JP 4589122B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- patent document
- inhibitor
- pde
- phosphodiesterase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002350804 | 2002-12-03 | ||
JP2002350804 | 2002-12-03 | ||
PCT/JP2003/015315 WO2004050091A1 (fr) | 2002-12-03 | 2003-12-01 | Inhibiteurs de phosphodiesterase 10a |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010144691A Division JP5192517B2 (ja) | 2002-12-03 | 2010-06-25 | 治療又は予防薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2004050091A1 JPWO2004050091A1 (ja) | 2006-03-30 |
JP4589122B2 true JP4589122B2 (ja) | 2010-12-01 |
Family
ID=32463120
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004556869A Expired - Fee Related JP4589122B2 (ja) | 2002-12-03 | 2003-12-01 | ホスホジエステラーゼ10a阻害剤 |
JP2010144691A Expired - Fee Related JP5192517B2 (ja) | 2002-12-03 | 2010-06-25 | 治療又は予防薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010144691A Expired - Fee Related JP5192517B2 (ja) | 2002-12-03 | 2010-06-25 | 治療又は予防薬 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20060106054A1 (fr) |
EP (1) | EP1570847B1 (fr) |
JP (2) | JP4589122B2 (fr) |
AU (1) | AU2003302588A1 (fr) |
CA (1) | CA2508194C (fr) |
WO (1) | WO2004050091A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6953774B2 (en) * | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
US20060106054A1 (en) * | 2002-12-03 | 2006-05-18 | Michiaki Nagasawa | Phosphodiesterase 10a inhibitors |
US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
RU2008116720A (ru) * | 2005-09-26 | 2009-11-10 | Эвиджен, Инк. (Us) | Способы лечения наркозависимости и пагубных привычек в поведении |
EP2026804A1 (fr) * | 2006-05-31 | 2009-02-25 | Avigen, Inc. | Ibudilast destiné à inhiber l'activité du facteur inhibiteur de la migration des macrophages (mif) |
WO2009017625A1 (fr) * | 2007-07-27 | 2009-02-05 | Avigen, Inc. | Traitement de la dépression, de la psychose et de l'anxiété |
WO2010005520A2 (fr) * | 2008-06-30 | 2010-01-14 | Concert Pharmaceuticals, Inc. | Dérivés de 2-alkyl-3-acylpyrazolo[1,5-a]pyridines |
MX2012003469A (es) * | 2009-09-24 | 2012-04-19 | Hoffmann La Roche | Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a. |
EP2604607A4 (fr) * | 2010-08-12 | 2014-01-01 | Kyorin Seiyaku Kk | Agent de prévention et de traitement d'une stéatohépatite d'origine non alcoolique |
WO2015006689A1 (fr) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Traitement et diagnostic du cancer et d'états précancéreux à l'aide d'inhibiteurs de pde10a et procédés pour mesurer l'expression de pde10a |
US11770855B2 (en) | 2016-10-19 | 2023-09-26 | Qualcomm Incorporated | Random access channel (RACH) procedure design |
US10433342B2 (en) | 2016-10-19 | 2019-10-01 | Qualcomm Incorporated | Enhanced random access channel (RACH) procedure |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02131424A (ja) * | 1988-11-11 | 1990-05-21 | Kyorin Pharmaceut Co Ltd | 記憶障害改善薬 |
WO2000009127A1 (fr) * | 1998-08-10 | 2000-02-24 | Kyorin Pharmaceutical Co., Ltd. | Traitements contre la sclerose en plaques |
WO2002066480A2 (fr) * | 2001-02-20 | 2002-08-29 | Astrazeneca Ab | 2-arylamino-pyrimidines pour le traitement de troubles associes a gsk3 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265577B1 (en) * | 1996-10-04 | 2001-07-24 | Kyorin Pharmaceuticals Co., Ltd. | Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof |
JP4293294B2 (ja) * | 1998-04-24 | 2009-07-08 | 藤原 道弘 | 痴呆改善薬 |
JP2000224992A (ja) * | 1998-11-30 | 2000-08-15 | Tanabe Seiyaku Co Ltd | 新規ホスホジエステラーゼ及びその遺伝子 |
WO2001024781A2 (fr) * | 1999-10-07 | 2001-04-12 | Novaneuron Inc. | Gene necessaire a la fonction striatale, ses applications et composes permettant de moduler ce gene |
WO2001040226A1 (fr) * | 1999-11-30 | 2001-06-07 | Toray Industries, Inc. | Agents permettant de stimuler l'apprentissage ou la memoire |
US20060106054A1 (en) * | 2002-12-03 | 2006-05-18 | Michiaki Nagasawa | Phosphodiesterase 10a inhibitors |
-
2003
- 2003-12-01 US US10/537,313 patent/US20060106054A1/en not_active Abandoned
- 2003-12-01 EP EP03812356A patent/EP1570847B1/fr not_active Expired - Fee Related
- 2003-12-01 CA CA2508194A patent/CA2508194C/fr not_active Expired - Fee Related
- 2003-12-01 JP JP2004556869A patent/JP4589122B2/ja not_active Expired - Fee Related
- 2003-12-01 WO PCT/JP2003/015315 patent/WO2004050091A1/fr active Application Filing
- 2003-12-01 AU AU2003302588A patent/AU2003302588A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/980,526 patent/US7846942B2/en not_active Expired - Fee Related
-
2010
- 2010-06-25 JP JP2010144691A patent/JP5192517B2/ja not_active Expired - Fee Related
- 2010-10-27 US US12/913,094 patent/US8404710B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02131424A (ja) * | 1988-11-11 | 1990-05-21 | Kyorin Pharmaceut Co Ltd | 記憶障害改善薬 |
WO2000009127A1 (fr) * | 1998-08-10 | 2000-02-24 | Kyorin Pharmaceutical Co., Ltd. | Traitements contre la sclerose en plaques |
WO2002066480A2 (fr) * | 2001-02-20 | 2002-08-29 | Astrazeneca Ab | 2-arylamino-pyrimidines pour le traitement de troubles associes a gsk3 |
Also Published As
Publication number | Publication date |
---|---|
EP1570847A1 (fr) | 2005-09-07 |
CA2508194C (fr) | 2011-05-24 |
AU2003302588A1 (en) | 2004-06-23 |
EP1570847A4 (fr) | 2008-10-08 |
EP1570847B1 (fr) | 2012-04-25 |
US8404710B2 (en) | 2013-03-26 |
CA2508194A1 (fr) | 2004-06-17 |
JP5192517B2 (ja) | 2013-05-08 |
US20080108650A1 (en) | 2008-05-08 |
JP2010248224A (ja) | 2010-11-04 |
JPWO2004050091A1 (ja) | 2006-03-30 |
US7846942B2 (en) | 2010-12-07 |
US20060106054A1 (en) | 2006-05-18 |
WO2004050091A1 (fr) | 2004-06-17 |
US20110039882A1 (en) | 2011-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5192517B2 (ja) | 治療又は予防薬 | |
JP5824698B2 (ja) | Hsp90の阻害による神経変性疾患の処置 | |
JP2014530872A (ja) | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ | |
AU2012325911B2 (en) | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | |
US20110319411A1 (en) | Isoindolinone and related analogs as sirtuin modulators | |
TW200424206A (en) | Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases | |
JP2018062526A (ja) | mTOR経路関連疾患を治療するための化合物 | |
FR2912744A1 (fr) | Composes pyrrolo[2,3-b]pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations. | |
JP2011503066A (ja) | 可溶化チアゾロピリジン誘導体 | |
WO2008130619A2 (fr) | Inhibiteurs des ampc phosphodiestérases | |
EP2968322A2 (fr) | Modulateurs de map kinase et utilisations de ceux-ci | |
JP2019531285A (ja) | 新規使用 | |
US11851427B2 (en) | Phosphodiesterase inhibitors and uses thereof | |
WO2013040526A1 (fr) | Composés antimicrobiens | |
KR101709731B1 (ko) | 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도 | |
WO2013109738A1 (fr) | Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci | |
JPWO2008050600A1 (ja) | 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100625 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4589122 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |